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Abstract
Adenosine A2A receptors (A2ARs) are thought to interact negatively with the dopamine D2 receptor (D2R), so selective A2AR
antagonists have attracted attention as novel treatments for Parkinson’s disease (PD). However, no information about the
receptor in living patients with PD is available. The purpose of this study was to investigate the relationship between A2ARs
and the dopaminergic system in the striata of drug-naı ¨ve PD patients and PD patients with dyskinesia, and alteration of
these receptors after antiparkinsonian therapy. We measured binding ability of striatal A2ARs using positron emission
tomography (PET) with [7-methyl-
11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([
11C]TMSX) in nine drug-naı ¨ve
patients with PD, seven PD patients with mild dyskinesia and six elderly control subjects using PET. The patients and eight
normal control subjects were also examined for binding ability of dopamine transporters and D2Rs. Seven of the drug-naı ¨ve
patients underwent a second series of PET scans following therapy. We found that the distribution volume ratio of A2ARs in
the putamen were larger in the dyskinesic patients than in the control subjects (p,0.05, Tukey-Kramer post hoc test). In the
drug-naı ¨ve patients, the binding ability of the A2ARs in the putamen, but not in the head of caudate nucleus, was
significantly lower on the more affected side than on the less affected side (p,0.05, paired t-test). In addition, the A2ARs
were significantly increased after antiparkinsonian therapy in the bilateral putamen of the drug-naı ¨ve patients (p,0.05,
paired t-test) but not in the bilateral head of caudate nucleus. Our study demonstrated that the A2ARs in the putamen were
increased in the PD patients with dyskinesia, and also suggest that the A2ARs in the putamen compensate for the
asymmetrical decrease of dopamine in drug-naı ¨ve PD patients and that antiparkinsonian therapy increases the A2ARs in the
putamen. The A2ARs may play an important role in regulation of parkinsonism in PD.
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Introduction
Parkinson’s disease (PD) is a progressive degenerative neuro-
logical disorder characterized clinically by resting tremor,
bradykinesia, cogwheel rigidity, and postural instability [1]. These
symptoms result primarily from the loss of dopaminergic neurons
in the substantia nigra and can be reduced by levodopa, which
replenishes dopamine, and dopamine agonists.
Adenosine is as an endogenous modulator of synaptic function
in the central nervous system [2], and its effects are mediated by at
least four receptor subtypes: A1,A 2A,A 2B, and A3 [3]. Adenosine
A1 receptors (A1Rs) are widely distributed throughout the entire
brain, while adenosine A2A receptors (A2ARs) are enriched in the
basal ganglia [4,5]. The A2AR is known to stimulate adenylyl
cyclase and interacts with the dopamine D2 receptor (D2R)
negatively at the level of second messengers and beyond [5]. The
A1R is known to inhibit adenylyl cyclase.
Recently, A2AR antagonists have attracted attention as
potential non-dopaminergic therapies for PD. For example,
caffeine is a nonselective adenosine receptor antagonist and is
known to reduce the risk of developing PD [6,7]. In addition,
theophylline, which is also a nonselective adenosine receptor
antagonist, was expected to be a promising agent for the treatment
of PD [8]. However, findings from clinical trials of both caffeine
and theophylline have been unimpressive [9,10]. The selective
A2AR antagonists was developed as novel nondopaminergic
agents for PD [11] and provides antiparkinsonian benefit without
causing or worsening dyskinesia, which is one of the most
inconvenient side effects of dopaminergic therapy [12]. A
postmortem study reported that the density of A2AR binding
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8sites in PD was comparable to that found in the normal subjects,
while the density in the basal ganglia was lower in patients with
Huntington’s chorea than in normal subjects [13]. However,
another study using in situ hybridization and autoradiography
suggested that A2ARs were involved in the development of
dyskinesia following long-term levodopa therapy in PD [14].
Therefore, A2ARs may be involved in the appearance of the side
effects of antiparkinsonian agents. Although the A2AR has
attracted much attention in PD therapies, clinical evidence
describing A2ARs in living PD patients, such as drug-naı ¨ve
patients, is lacking.
We developed PET ligands for mapping adenosine receptors,
and we successfully visualized A1Rs with [1-methyl-
11C]8-dicyclo-
propylmethyl-1-methyl-3-propylxanthine ([
11C]MPDX) [15,16]
and A2ARs with [7-methyl-
11C]-(E)-8-(3,4,5-trimethoxystyryl)-
1,3,7-trimethylxanthine ([
11C]TMSX, Fig. 1) [17,18,19,20].
[
11C]TMSX has a xanthine structure and is an analog of
istradefylline. In addition, the specific binding of [
11C]TMSX to
A2ARs was confirmed with a theophylline challenge [21]. We
performed test-retest studies and optimized the kinetics for
[
11C]TMSX PET in normal subjects, thus confirming good
reproducibility of [
11C]TMSX PET in the putamen. In this study,
we investigated A2ARs in the striata of drug-naı ¨ve PD patients
and PD patients with dyskinesia, and alteration of A2ARs after
antiparkinsonian therapy using [
11C]TMSX PET.
Results
Figure 2 shows representative PET images for normal subjects,
a drug-naı ¨ve PD patient before and after anti-parkinsonian
therapy, and a PD patinet with dyskinesia.
Group comparison
There was no significant difference with age among the three
groups, i. e. the drug naı ¨ve PD patients (five men and four women,
mean age 64.665.7 years, Table 1), the PD patients with
dyskinesia (two men and five women, mean age 65.067.3 years,
Table 2) and the normal subjects (three men and three women,
mean age 60.768.5 years). Rate of female was slightly large in the
patients with dyskinesia [22], although not significant. In the PD,
duration of disease was longer in the patients with dyskinesia
(11.167.2 years) than the drug naı ¨ve patients (2.061.2 years,
p,0.001, unpaired t-test). There was no significant difference with
the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III)
between the drug naı ¨ve patients (17.7613.2) and the patients with
dyskinesia (12.6611.2).
The distribution volume ratio (DVR) for [
11C]TMSX in the
bilateral putamen of patients with dyskinesia was larger with that
normal controls (p,0.05), although that of drug-naı ¨ve patients was
comparable with that of normal controls (Table 3). In the head of
the caudate nucleus, the DVR of patients with dyskinesia was
alightly larger than that of other two groups, although not
significant.
In both the bilateral putamen and the head of the caudate
nucleus, the uptake ratio index (URI) of [
11C]2b-carbomethoxy-
3b-(4-fluorophenyl) tropane ([
11C]CFT), a marker for presynaptic
dopamine transporter (DAT), in the bilateral putamen was
significantly lower in the drug-naı ¨ve patients and patients with
dyskinesia than in the normal controls (Table 3). The URI of
[
11C]raclopride ([
11C]RAC), a marker for postsynaptic D2R, in
the bilateral striata was lower in the patients with dyskinesia than
in the controls and drug-naı ¨ve patients (Table 3).
Asymmetry in drug-naı ¨ve state
When we examined the asymmetrical symptoms in the early
phase of PD as they relate to the PET images, we found that the
DVR for [
11C]TMSX in the putamen was significantly lower on
the more affected side than on the less affected side in the PD
patients (Table 4). In contrast, the head of the caudate nucleus
showed no significant differences between the more affected side
and the less affected side according to DVRs for [
11C]TMSX.
The URI for [
11C]CFT in the putamen was significantly lower
on the more affected side than on the less affected side in the drug-
naı ¨ve patients, and the URI for [
11C]RAC was significantly higher
on the more affected side than on the less affected side (Table 4).
In the head of the caudate nucleus, there was no significant
difference between the more affected side and the less affected side
in the URI for either [
11C]CFT or [
11C]RAC.
Figure 3 demonstrates the lack of significant correlation among
the DVR for [
11C]TMSX, the URI for [
11C]CFT and the URI
for [
11C]RAC in the bilateral striata of drug-naı ¨ve patients.
Specifically, there was no significant correlation among the
following variables; the DVR for [
11C]TMSX versus the URI
for [
11C]CFT (Figure 3A and 3D), the DVR for [
11C]TMSX
versus the URI for [
11C]RAC (Figure 3B and 3E), and the URI for
[
11C]CFT versus the URI for [
11C]RAC (Figure 3C and 3F).
Post-therapeutic state
In the seven PD patients with follow-up studies, the DVR for
[
11C]TMSX in the bilateral putamen was significantly increased in
the post-therapeutic state relative to the drug-naı ¨ve state (Table 5).
The URIs for both [
11C]CFT and [
11C]RAC in the bilateral
Figure 1. Structure of [
11C]TMSX.
doi:10.1371/journal.pone.0017338.g001
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than the drug-naı ¨ve state.
In the head of the caudate nucleus bilaterally, the URIs for
[
11C]CFT and [
11C]RAC were significantly decreased in the post-
therapeutic state than the drug-naı ¨ve state, but there was no
significant difference in the DVR for [
11C]TMSX.
Discussion
As previous stidies reported [13,14,23], our PET study
demonstrates that the putaminal binding ability of A2ARs was
increased in the PD patients with dyskinesia, and that there was no
significant difference in the striatal binding ability of A2ARs
between drug-naı ¨ve PD patients and normal controls. However, in
drawing attention to the asymmetrical symptoms in drug-naı ¨ve
PD, our study suggests that A2ARs were asymmetrically down-
regulated in the putamen but not in the head of the caudate
nucleus. The function of A2ARs is thought to be opposite to that
of D2Rs [5]. PET studies using [
11C]RAC have shown elevated
binding of D2Rs in the putamen in early PD [24,25,26], due to
decreased endogenous dopamine and weak D2R affinity for
[
11C]RAC [27]. However, a postmortem study reported that the
density of the D2R binding sites was higher in PD patients than
normal controls [28]. Therefore, D2Rs are thought to be up-
regulated in the putamen of the patients with advanced PD. Past
studies indicated that 80% loss of dopaminergic neurons in the
substantia nigra was needed to be developed to symptoms of PD,
because such compensatory change of D2Rs is thought to delay
the onset of symptoms of PD [29]. We reported on the
asymmetrical compensation of the sigma1 receptor for the
reduction of dopamine in the putamen in early PD [30]. Our
study in the drug-naı ¨ve state suggested that A2ARs might play an
important role in inhibition of asymmetrical parkinsonism in PD
along with D2Rs and sigma1 receptors.
In the patients with PD, DATs in the putamen were reduced in
the diskinesic patients relative to the drug-naı ¨ve patients, and
reduced in the post-therapeutic state relative to the drug-naı ¨ve
state. These findings were considered to reflect the progression of
PD. The uptake of [
11C]RAC in the putamen was reduced in the
diskinesic patietnts relative to the drug-naı ¨ve patients, and reduced
Figure 2. PET images for normal subjects, a drug-naı ¨ve patient with Parkinson’s disease (PD), and a PD patient with dyskinesia. The
normal subjects are a 63-year-old female for [
11C]TMSX, and a 63-year-old male for [
11C]CFT and [
11C]RAC (A). The drug-naı ¨ve patient is a 60-year-old
male with right-dominant parkinsonism, and underwent two series of PET scans before (B) and after anti-parkinsonian therapy (C). The patients did
not developed dyskinesia at a second series of PET scan in the post-therapeutic state. The DVR of [
11C]TMSX was smaller in the left putamen than in
the right and was increased after treatment with anti-parkinsonian therapy for 14 months. The uptake of [
11C]CFT was reduced in the putamen,
especially on the left. The uptake of [
11C]RAC was preserved in the striatum and was larger in the left putamen than in the right. The relative uptake of
[
11C]CFT and [
11C]RAC in the putamen was lower in the post-therapeutic state than in the drug-naı ¨ve state. The PD patient with dyskinesia is a 65-
year-old male with right-dominant parkinsonism (D). His disease duration was 19 years. The DVR of [
11C]TMSX was increased in the striata. The uptake
of [
11C]CFT was significantly decreased in the putamen.
doi:10.1371/journal.pone.0017338.g002
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findings are consistent with the compensatory change of D2Rs.
We think that there are two possible reasons. First, [
11C]RAC may
have competed with the D2R agonists and increased endogenous
dopamine due to levodopa, thus decreasing the binding of
[
11C]RAC to D2Rs. Second, the antiparkinsonian therapy may
have abrogated the compensation of D2R due to the decrease in
the dopamine. These factors can affect the binding of [
11C]RAC
in the striata, and it is difficult to detect the up-regulation of D2R
using [
11C]RAC PET in the patients with PD.
Striatal GABAergic medium spiny neurons (MSNs) represent
more than 90% of striatal neurons, and A2ARs are highly
Table 1. Demographic and clinical data of drug-naı ¨ve patients with Parkinson’s disease.
No
Age
(years) Gender
Duration
from onset
(years) Symptom
Hoehn
& Yahr
UPDRS-III
Pre-therapy
Duration
of therapy
(month)
Antiparkinsonian
agents at post-
therapy PET LED (mg)
UPDRS-III
Post-
therapy
1 72 F 2.0 R.L 1 5 7.0 Levodopa and
carbidopa
100 19
2 60 M 1.3 R.L 2 8 14.2 Pramipexole and
amantadine
75 6
3 58 F 3.0 R.L 4 41 15.9 Pramipexole,
levodopa and
carbidopa
450 25
4 68 F 0.5 R.L 2 23 15.9 Pramipexole,
amantadine,
levodopa and
carbidopa
137.5 4
5 64 M 1.2 L.R 1 6 12.9 Pramipexole 150 7
6 56 M 0.7 L.R 2.5 10 20.8 Pramipexole and
amantadine
200 21
7 68 M 3.0 L.R 3 18 14.7 Ropinirole, selegiline,
droxidopa, levodopa
and benserazide
825.5 21
8 71 M 4.0 R.L 1.5 12 – – – –
9 64 F 2.0 L.R 2.5 36 – – – –
Mean6SD 64.665.7 2.061.2 2.261.0 17.7613.2 14.5613.2 276.96272.2 14.768.7
UPDRS-III; Unified Parkinson’s Disease Rating Scale part III. LED; levodopa-equivalent dose.
doi:10.1371/journal.pone.0017338.t001
Table 2. Demographic and clinical data of dyskinesic patients with Parkinson’s disease.
No Age (years) Gender
Duration
from onset
(years) Symptom
Hoehn &
Yahr UPDRS-III UPDRS-IV Antiparkinsonian agents LED (mg)
17 3 F 5R .L 2 8 5 Pramipexole, Levodopa,
carbidopa and entacapone
416.7
2 65 M 19 R.L 3 9 6 Cabergoline, trihexyphenidyl
hydrochloride, droxidopa
levodopa and carbidopa
667.0
3 66 F 10 R.L 3 7 5 Trihexyphenidyl hydrochloride,
zonisamide, levodopa and
benserazide hydrochloride
300.0
45 0 F 2R .L 2 11 3 Pramipexole, levodopa and
carbidopa
750.0
56 6 F 9L .R 3 13 4 Pramipexole, levodopa and
carbidopa
225.0
6 65 M 11 L.R 2 3 7 Pramipexole, cabergoline,
amantadine, levodopa and
carbidopa
983.5
7 70 F 22 L.R 4 37 9 Pramipexole, trihexyphenidyl
hydrochloride, amantadine,
levodopa and carbidopa
500.0
Mean6SD 65.067.3 11.167.2 2.760.8 12.6611.2 5.662.0 548.96267.7
UPDRS-III; Unified Parkinson’s Disease Rating Scale part III. LED; levodopa-equivalent dose.
doi:10.1371/journal.pone.0017338.t002
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the striatonigral MSNs (direct pathway) [31,32]. Postmortem
studies demonstrated dendritic atrophy of MSNs during advanced
PD [33,34]. Therefore, an alteration in A2AR expression may be
involved in the dendritic atrophy in the MSNs.
Our study showed that the binding of [
11C]TMSX to A2ARs
was increased in the putamen in the PD patients with mild
dyskinesia. A postmortem study suggested that the messenger
ribonucleic acid (mRNA) of A2ARs and [
3H]SCH-58261-specific
binding to A2ARs were increased in the putamen of PD patients
with dyskinesia following long-term levodopa therapy [14].
Another study showed that mRNA levels for the A2ARs were
elevated in the putamen of levodopa-treated MPTP monkeys
compared with controls, although autoradiography with
[
3H]SCH-58261 could not showed significant difference [23].
Our study also showed that the binding of [
11C]TMSX was
increased in the putamen after the antiparkinsonian therapy. The
finding may reflect alteration in compensation for the decrease of
dopamine in the patients with PD. The drug-naı ¨ve patients in this
study did not develop dyskinesia by the time of second series of
PET scans. Therefore, our study suggests that the increase in
putaminal A2ARs after antiparkinsonian therapy preceded the
development of dyskinesia in patients with PD. Dyskinesia may be
involved in the additional gain of the A2ARs. We may predict the
onset of dyskinesia using sequential [
11C]TMSX PET examina-
tion. Moreover, a recent study suggested that dyskinesia may
involve not only A2ARs but also A1Rs [35]. Further PET studies
with [
11C]MPDX and [
11C]TMSX will be needed to clarify this
issue.
In conclusion, [
11C]TMSX PET demonstrated that the
distribution of A2ARs was increased in the putamen in PD
patients with dyskinesia. A2ARs was asymmetrically down-
regulated in the putamen in drug-naı ¨ve patients with PD, and
the asymmetrical regulation of A2ARs seems to be involved in
compensation for the decrease in dopamine. Our study also
showed that the A2ARs were increased in the putamen after
antiparkinsonian therapy.
Materials and Methods
Subjects
We studied nine drug-naı ¨ve patients with PD. Table 1
summarizes the clinical profiles of the patients. All patients were
right-handed. Their PD diagnoses were based on their medical
histories, physical and neurological examinations, laboratory tests,
and magnetic resonance imaging (MRI) studies, to rule out other
diseases [1,36,37]. They had no medical histories of bronchial
asthma and did not take theophylline regularly. To confirm early
diagnosis of PD, each patient was also examined for DATs and
D2Rs by PET using [
11C]CFT and [
11C]RAC, respectively.
Specifically, we confirmed low binding of [
11C]CFT and normal
or high uptake of [
11C]RAC in the putamen of all patients
[38,39,40]. After PET examinations for drug naı ¨ve state, we also
Table 3. The DVRs for [
11C]TMSX and URIs for [
11C]CFT and [
11C]RAC in the striata of normal controls, drug-naı ¨ve patients with
Parkinson’s disease (PD) and PD patients with dyskinesia.
Radiopharmaceutical Normal Control Drug-naı ¨ve PD PD with dyskinesia
Putamen
[
11C]TMSX 1.4760.11 1.4860.10 1.5860.15
*
[
11C]CFT 2.6760.49 1.1460.33
{ 0.6560.24
{,
{{
[
11C]RAC 3.1060.42 3.4360.55 2.8660.70
**
Head of the caudate nucleus
[
11C]TMSX 1.3860.08 1.3760.09 1.4460.15
[
11C]CFT 2.5260.54 1.8360.35
1 1.3660.39
{,**
[
11C]RAC 2.7060.48 2.5060.37 1.8460.49
{,
11
Values are mean 6 SD (Drug-naı ¨ve PD: n = 9; PD with dyskinesia: n = 7; normal: n=6f o r[
11C]TMSX and n =8f o r[
11C]CFT and [
11C]RAC). Binding of [
11C]TMSX was
evaluated as the distribution volume ratio (DVR) and binding of [
11C]CFT or [
11C]RAC was expressed as the uptake ratio index (URI).
*p,0.05 (vs normals),
**p,0.05 (vs drug-naı ¨ve),
{p,0.005 (vs normal),
{{p,0.005 (vs drug-naı ¨ve PD),
1p,0.0005 (vs normal),
11p,0.0005 (vs drug-naı ¨ve),
{p,0.0001 (vs normal),
{{p,0.0001 (vs drug-naı ¨ve PD, Tukey-Kramer post hoc test).
doi:10.1371/journal.pone.0017338.t003
Table 4. The asymmetry in DVRs for [11C]TMSX and URIs for
[11C]CFT and [11C]RAC in the striata of drug-naı ¨ve patients
with Parkinson’s disease.
Radiopharmaceutical More affected side Less affected side
Putamen
[
11C]TMSX 1.4660.11 1.5060.10*
[
11C]CFT 0.9860.30 1.2960.29
{
[
11C]RAC 3.5960.53 3.2760.56
{
Head of the caudate nucleus
[
11C]TMSX 1.3860.10 1.3660.08
[
11C]CFT 1.7860.33 1.8960.38
[
11C]RAC 2.5260.37 2.4760.39
Values are mean 6 SD (PD: n = 9). Binding of [
11C]TMSX was evaluated as the
distribution volume ratio (DVR) and binding of [
11C]CFT or [
11C]RAC was
expressed as the uptake ratio index (URI).
*p,0.05,
{p,0.005 (paired t-test).
doi:10.1371/journal.pone.0017338.t004
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the parkinsonian symptoms by antiparkinsonian therapy, and that
their diagnoses of PD remained unchanged in more than two years
of observation. The patients did not experience hallucinations or
dementia [41]. UPDRS-III was used to evaluate motor disability.
Seven of the nine patients were re-examined with [
11C]TMSX,
[
11C]CFT and [
11C]RAC PET 14.564.1 months after starting
antiparkinsonian therapy (Patients 1–7 in Table 1). The daily
levodopa equivalent dose (LED) was calculated as follow: levodopa
(mg) + levodopa (mg) 61/3 (if on entacapone) + levodopa (mg)
60.026selegiline (mg) + pramipexole (mg)6100 + ropinirole (mg)
616.7 + cabergoline (mg) 667 + pergolide (mg) 6100 +
bromocriptine (mg) 610. The LED for patients that underwent
follow-up studies ranged from 75.0 to 825.5 mg (276.96272.2 mg)
at the time of post-therapeutic PET scanning. No patients
developed dyskinesia during the period of this study. The
administration of antiparkinsonian agents was not stopped before
obtaining the PET scans at the therapeutic state.
We also studied advanced PD patients with mild dyskinesia.
Table 2 summarizes the clinical profiles of the patients. All patients
were right-handed. The LED for patients ranged from 225.0 to
983.5 mg (548.96267.7 mg) at the time of PET scanning. The
Unified Parkinson’s Disease Rating Scale part IV (UPDRS-IV)
was used to evaluate drug side effects such as dyskinesia. The
dyskinesia of the patients was mild, and they could acquire PET
examinations without any trouble caused by undesirable move-
ments during the PET scanning.
For [
11C]TMSX PET scanning, the control group consisted of
six volunteers. For [
11C]CFT and [
11C]RAC PET scanning,
another control group was used, which consisted of eight
volunteers (five men and three women, mean age 6 SD,
62.366.9 years). The subjects in these control groups were all
Figure 3. Scattergrams for binding parameters of [
11C]TMSX, [
11C]CFT and [
11C]RAC in the striata of drug-naı ¨ve patients. The binding
parameter for [
11C]TMSX was expressed as DVR, and parameters for [
11C]CFT and [
11C]RAC were expressed as URI. There was no significant correlation
among these variables.
doi:10.1371/journal.pone.0017338.g003
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or any abnormalities on physical or neurological examinations. In
addition, they did not take medications known to affect brain
function and did not have a history of alcoholism. The normal
subjects for [
11C]TMSX PET had no medical histories of
bronchial asthma.
The study protocols were approved by the Ethics Committee of
the Tokyo Metropolitan Institute of Gerontology. Written
informed consent was obtained from all subjects who participated
in this study.
[
11C]TMSX PET
PET was performed in the Tokyo Metropolitan Institute of
Gerontology Positron Medical Center with an SET-2400W PET
scanner (Shimadzu Co., Kyoto, Japan) [46]. Image manipulations
were carried out on a MacBookPro computer with medical image
processing software Dr. View/Linux R2.5 (AJS Inc., Tokyo,
Japan) implemented in CentOS 5.4 (The CentOS Project, http://
www.centos.org/) and Parallels Desktop 5 (Parallels Holdings,
Ltd., Renton, WA, US).
All subjects avoided caffeine consumption over 12 hours before
obtaining the [
11C]TMSX PET scans. The [
11C]TMSX was
prepared as previously described [42]. Specific activity at the time
of injection ranged from 40.6 to 119.5 GBq/mmol (69.6620.8
GBq/mmol). After a transmission scan with a rotating
68Ga/
68Ge
line source to correct for the photon attenuation using the
attenuation map, a dynamic series of decay-corrected PET data
was acquired for 60 minutes using the 2D mode starting at the
time of 700 MBq of [
11C]TMSX injection without arterial blood
sampling. A total 27 of frames were taken, including six 10-s
frames, three 30-s frames, five 1 min frames, five 2.5 min frames,
and eight 5 min frames. All procedures for [
11C]TMSX PET
scanning were performed under dim light to prevent photoisom-
erization of the [
11C]TMSX [42,43].
We generated early images for [
11C]TMSX PET by summing
frames of the dynamic scan from 0 to 10 minutes [44], and we
used these images as a reference for placing ROIs on the PET
images of dynamic scans. We placed circular ROIs 10 mm in
diameter on the PET images over the putamen and the head of
the caudate nucleus bilaterally. In addition, we placed ROIs over
the frontal lobe, temporal lobe, and occipital lobe to use as
reference regions for kinetics analysis. We calculated regional time
activity curves in the tissue (tTACs) from the dynamic data and
ROIs, and we evaluated binding of [
11C]TMSX to A2ARs in the
striata as a DVR using tTACs, a graphical analysis with the
cerebral cortex as the reference region [45]. A kinetics analysis of
the tTACs was performed using programs implemented in
MATLAB version 7.04 (The Mathworks, Natick, MA, USA).
[
11C]CFT and [
11C]RAC PET
The [
11C]CFT was prepared as previously described [47]. The
specific activity at the time of injection ranged from 10.3 to 300.3
GBq/mmol (51.9660.1 GBq/mmol). Transmission data were
acquired with a rotating
68Ga/
68Ge rod source for attenuation
correction. Each subject received an intravenous injection of 300
MBq of [
11C]CFT. Beginning 75 minutes after the injection, an
emission scan was performed using the 3D mode, which lasted 15
minutes.
The [
11C]RAC was prepared as previously described [48]. The
specific activity at the time of injection ranged from 5.7 to 280.0
GBq/mmol (63.1657.4 GBq/mmol). Transmission data were
acquired with a rotating
68Ga/
68Ge rod source for attenuation
correction. Each subject received an intravenous injection of 300
MBq of [
11C]RAC. Beginning 40 minutes after the injection, an
emission scan was performed using the 3D mode, which lasted 15
minutes.
Circular regions of interest (ROIs) 10 mm in diameter were
positioned on the PET images over the bilateral putamen, the
head of the caudate nucleus and the cerebellar hemisphere. For a
semi-quantitative analysis of the [
11C]CFT and [
11C]RAC PET,
we calculated URI in the putamen and the head of the caudate
nucleus [49] as follows:
URI~
AS{AC
AC
where AS is the radioactivity in the ipsilateral putamen or the head
of the caudate nucleus, and AC is the radioactivity of the bilateral
cerebellar hemispheres.
Statistics
Among the drug naı ¨ve PD patients, the PD patients with
dyskinesia and the normal subjects, One-way analysis of variance
with Tukey-Kramer post hoc test were used to compare DVRs for
[
11C]TMSX PET, URIs for [
11C]CFT and [
11C]RAC PET, and
age. Where only two groups were compared, unpaired t test was
used. Group difference in gender was calculated with the use of the
chi-square test of proportions. In the drug naı ¨ve patients, striata
from the more affected and the less affected side were compared,
and the effect of therapeutic treatment on the striata was evaluated
by the paired t-test. Regression analyses were used for comparison
among binding parameters of [
11C]TMSX, [
11C]CFT and
[
11C]RAC. The level of significance was set to p,0.05. Statistical
values were computed using the software package JMP version
9.0.0 (SAS Institute Inc., Cary, NC, USA) on a Macintosh
computer.
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Table 5. Therapeutic change in DVRs for [
11C]TMSX and URIs
for [
11C]CFT and [
11C]RAC in the bilateral striata in the seven
patients with Parkinson’s disease.
Radiopharmaceutical Drug-naı ¨ve state
Post-therapeutic
state
Putamen
[
11C]TMSX 1.4660.12 1.5060.09*
[
11C]CFT 1.1260.36 0.8860.23
{
[
11C]RAC 3.4460.42 2.7660.78
{
Head of the caudate nucleus
[
11C]TMSX 1.3660.09 1.3760.11
[
11C]CFT 1.7460.29 1.4860.23
1
[
11C]RAC 2.5660.37 2.0160.52
{
Values are mean 6 SD (n = 7). Binding of [
11C]TMSX was evaluated as the
distribution volume ratio (DVR and binding of [
11C]CFT or [
11C]RAC was
expressed as the uptake ratio index (URI).
*p,0.05,
{p,0.005,
1p,0.001,
{p,0.0005 (paired t-test).
doi:10.1371/journal.pone.0017338.t005
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